Triptorelin Market Higher Growth Rate & Forecast 2018 – 2026 | Ipsen, Bachem, Ferring Pharmaceuticals, Chengdu Tiantaishan pharmaceutical, Tecnofarma

Gonadotropin-releasing hormone (GnRH) agonists have greater safety and efficacy profile than estrogens and anti-androgens among various therapies of achieving medical castration. Furthermore, slow-release formulations of GnRH agonists offer patients flexibility, improves quality of life, and eventually reduce cost.

Most of the times, prostate cancer progresses with increasing testosterone hormone. Moreover, the production of testosterone can be stopped by surgically removing the testicles or thorough medication therapy. Triptorelin is GnRH agonists which is designed to stop the tentacles from making testosterone. This eventually reduces testosterone levels and minimizes progression of prostate cancer.

Triptorelin is a decapeptide analogue of Luteinising Hormone-Releasing Hormone (LHRH, also called gonadotropin-releasing hormone [GnRH]). Triptorelin is extensively used in palliative treatment of hormone dependent advanced prostate cancer.

Request For Sample Copy Of This Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1963

Market Dynamics
Triptorelin market is expected to witness lucrative growth opportunities during forecast period, owing to increasing incidence of prostate cancer and salivary gland cancer and increasing prevalence of central precocious puberty among the young patients below age eight and nine years, worldwide. For instance, according to National Organization for Rare Disorders (NORD), 2016 data findings, Central Precocious Puberty (CPP), accounted for 1 to 5 in 10,000 children with a female to male ratio of about 20:1, in U.S.

In March 2017, Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, in coordination with fourteen other European regulatory agencies approved a new indication of Decapeptyl (triptorelin). According to these new indication, Decapeptyl (triptorelin) will be used as adjuvant treatment in combination with tamoxifen or aromatase inhibitor for endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy. This would enhance the revenue for growth for triptorelin market, during forecast period.

Furthermore, higher efficacy and tolerability of triptorelin in suppression of gonadotropin secretion in prostate cancer and precocious puberty is increasing adoption of triptorelin in the market.

Key features of the study:

This report provides in-depth analysis of triptorelin market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global triptorelin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
Extended Application of Triptorelin in Various Treatment Modalities is expected to Drive Market Growthduring the Forecast Period

The GnRH agonist, triptorelin is a first-line hormonal therapy, which offers efficacy and safety in clinical trials of patients with non-metastatic or metastatic prostate cancer. Furthermore, triptorelin has been increasingly studied for varied treatment options, present in clinical development phases. For instance, GnRH analogue, triptorelin is being studied to analyze their efficacy and safety for HIV-1 reservoir reduction in Antiretroviral Therapy (ART) treated HIV-1 infected patients. According to ClinicalTrials.gov, in May 2018, this study was conducted by Immune System Regulation AB, and currently in phase II clinical stage.

Triptorelin is further being studied to analyze effects of adjuvant hormonal therapy treatments of Tamoxifen, Letrozole and Letrozole + Zoledronate on bone loss in breast cancer patients. According to ClinicalTrials.gov, in July 2017, this study was sponsored by National Cancer Institute (NCI), Naples; and currently present in phase III clinical stage. Moreover, triptorelin market shows lucrative revenue growth in the near future, with the successful completion of this study and potential launch of new products during the forecast period.

Increasing Prevalence of Prostate Cancer among Global Population is expected to Aid in Market Growth
Incensing prevalence of prostate cancer worldwide and wide applications of triptorelin in prostate cancer treatment to limit the cancer progression by reducing the testosterone synthesized by body is expected to drive growth of triptorelin market during the forecast period.

For instance, according to the World Cancer Research Fund (WCRF) International, 2012, over 1.1 million cases of prostate cancer were recorded, accounting for around 8% of all new cancer cases worldwide. Furthermore, around 68% of prostate cancer cases were registered in the developed economies. Highest incidence of prostate cancer was reported in Oceania and North America, while lowest incidence was reported in Asia and Africa.

Key players operating in triptorelin market include Ipsen, Bachem, Ferring Pharmaceuticals Pvt Ltd., Chengdu Tiantaishan pharmaceutical Co., Ltd., Tecnofarma, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.), Debiopharm Group, and Arbor Pharmaceuticals, LLC.

Download The PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1963

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr.Shah
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.